DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the MOREPEN LAB. LTD (MOREPENLAB) share price today?

MOREPEN LAB. LTD (MOREPENLAB) is trading at ₹58.9 on the NSE, down 3.17% on the day. Source: DocStoX.

What is the PE ratio of MOREPEN LAB. LTD?

MOREPEN LAB. LTD has a price-to-earnings (PE) ratio of 34.0 in the Healthcare sector.

What is the market capitalisation of MOREPEN LAB. LTD?

MOREPEN LAB. LTD has a market capitalisation of approximately ₹3,247 crore.

MOREPEN LAB. LTD

MOREPENLAB·NSE·Healthcare

₹58.90▼ -1.93 (-3.17%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹57.66

₹61.00

52W₹33

₹6582%

Open

₹60.90

High

₹61.00

Low

₹57.66

Prev Close

₹60.83

Volume

77.06L

VWAP

₹58.98

Snapshot

Key fundamentals

Market Cap

₹3,247 Cr

P/E Ratio

34.05Fair

P/B Ratio

2.62

EPS

₹1.73

Book Value

₹22.80

ROE

6.20%Weak

ROCE

8.00%Weak

Dividend Yield

0.33%

Debt / Equity

0.17Low

Face Value

₹2.00

52W High

₹64.58

52W Low

₹33.05

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹23

▼ 61.0%downside

Trading at ₹59 — 61% above our estimate

BearFair valueBull

₹20₹23₹30

/100

Business quality — Watch the fundamentals

Growth 67Profitability 12Efficiency 0Valuation 66

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (6%)

Strengths

Low debt relative to equity
Profit growing 35% a year

Risks

Weak returns on equity (6%)
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

6% ROE fading to 12% over ~3 yrs, on ₹23 book

₹21

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹30

Analyst target

No analyst coverage

—

Blended fair value₹23

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Profit growing 35% a year

Bear case

Weak returns on equity (6%)
Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

34.0Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

6.2%Weak

Above 15% is considered healthy for Indian equities

ROCE

8.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.17Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹3,247 Cr

P/B

2.62

EPS

₹1.73

Div Yield

0.33%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Reasonable

P/E 34.0×

Growth

Steady

+8% rev CAGR

Profitability

Modest

6.2% ROE

Financial health

Rock solid

D/E 0.17

Momentum

N/A

No technicals

Today

Trading activity

Delivery %35.2%

Turnover₹4544.55L Cr

Trades23,481

VWAP₹58.98

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+8.4%

+8.7%

10Y

+14.1%

Profit

+35.0%

-0.2%

10Y

+22.1%

EPS

+31.6%

-4.3%

10Y

+20.0%

Profile

Cons

Stock is trading at 2.69 times its book value
The company has delivered a poor sales growth of 8.73% over past five years.
Company has a low return on equity of 9.61% over last 3 years.
Earnings include an other income of Rs.47.1 Cr.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

36%

Promoter

Promoters

35.6%0.00

Public

50.0%-0.25

FII / FPI

1.6%-0.03

DII

1.3%0.00

Others

11.5%

Total shareholders

4,47,286-5,851 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter35.65%

FII1.59%

DII1.25%

Government0.01%

Public50.03%

Others11.47%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

MOREPEN LAB. LTD valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

MOREPEN LAB. LTD peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare MOREPEN LAB. LTD with peers

MOREPEN LAB. LTD vs SUN PHARMACEUTICAL IND L MOREPEN LAB. LTD vs DIVI S LABORATORIES LTD MOREPEN LAB. LTD vs TORRENT PHARMACEUTICALS L MOREPEN LAB. LTD vs APOLLO HOSPITALS ENTER. L MOREPEN LAB. LTD vs ZYDUS LIFESCIENCES LTD MOREPEN LAB. LTD vs CIPLA LTD

MOREPEN LAB. LTD

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

MOREPEN LAB. LTD valuation & research

MOREPEN LAB. LTD peers in Healthcare

Compare MOREPEN LAB. LTD with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Cons

Ownership breakdown

Ownership over time

Frequently asked questions